Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779922 | 0.93 | PNMT (0.54) | PNMTCYP2A6TAAR1ASIC3MAOB | |
| SCHEMBL9016348 | 0.85 | ASIC3 (0.57) | PNMTCYP2A6TAAR1ASIC3LOXL2 | |
| SCHEMBL6211230 | 0.79 | CYP2A6 (0.52) | CYP2A6TAAR1LOXL2TEC | |
| SCHEMBL29463734 | 0.78 | CYP2A6 (0.52) | PNMTCYP2A6TAAR1ASIC3LOXL2 | |
| SCHEMBL17907448 | 0.78 | CYP2A6 (0.52) | PNMTCYP2A6TAAR1ASIC3LOXL2 | |
| SCHEMBL4390898 | 0.77 | CYP2A6 (0.50) | CYP2A6TAAR1LOXL2TEC | |
| SCHEMBL15352347 | 0.77 | CYP2A6 (0.50) | CYP2A6TAAR1LOXL2TEC | |
| SCHEMBL21584423 | 0.77 | IDO1 (0.58) | CYP2A6TAAR1LOXL2TEC | |
| SCHEMBL15351609 | 0.77 | CYP2A6 (0.50) | CYP2A6MAOBTEC | |
| SCHEMBL11661526 | 0.77 | CYP2A6 (0.50) | CYP2A6CA12CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4494698-A2 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| EP-3661922-B1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-23 | — | — | EP | disclosed |
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-20 | — | — | US | disclosed |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-20 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220056028-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-24 | — | — | US | disclosed |
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-09 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2020-07-30 | — | — | US | disclosed |
| EP-3661922-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Dyax Corp. (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019028362-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-2657214-B1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | MITSUBISHI GAS CHEMICAL CO (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-8993774-B2 | Process for production of aromatic alcohol or heterocyclic aromatic alcohol | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2015-03-31 | — | — | US | disclosed |
| US-20130303775-A1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2013-11-14 | — | — | US | disclosed |
| EP-2657214-A1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | Mitsubishi Gas Chemical Company, Inc. (JP) | 2013-10-30 | — | — | EP | disclosed |
| WO-2004089903-A9 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER LAMBERT CO (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | PNMT 1725/4885CYP2A6 3468/4885TAAR1 3136/4885 |
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | KLKB1, KLK1, KLK5 | PNMT 1725/4885CYP2A6 3468/4885TAAR1 3136/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | PNMT 1882/4885CYP2A6 672/4885TAAR1 2367/4885 |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | PNMT 1725/4885CYP2A6 3468/4885TAAR1 3136/4885 |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | REN, ACE, HPN | PNMT 812/4885CYP2A6 4004/4885TAAR1 2213/4885 |
| US-20220056028-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | PNMT 1725/4885CYP2A6 3468/4885TAAR1 3136/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | PNMT 1882/4885CYP2A6 672/4885TAAR1 2367/4885 |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | PNMT 1725/4885CYP2A6 3468/4885TAAR1 3136/4885 |
| US-20130303775-A1 | PROCESS FOR PRODUCTION OF AROMATIC ALCOHOL OR HETEROCYCLIC AROMATIC ALCOHOL | ADH1C, ADH1A, ADH5 | PNMT 334/4885CYP2A6 278/4885TAAR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.